Sentetik Kannabinoidler: Bibliometrik Analiz

Öz

Amaç: Sentetik kannabinoidler (SC), yeni psikoaktif maddeler arasında en hızlı yayılan ve en endişe verici sınıflardan biridir. Başlangıçta bilimsel araştırmalar için sentezlenen bu bileşikler, güçlü psikoaktif etkileri nedeniyle hızla kötüye kullanılmaya başlanmıştır. Δ9-tetrahidrokanabinol (THC) ile karşılaştırıldığında, çoğu SC kannabinoid reseptörlerinde tam agonist olarak işlev görerek etkinliği artırmakta ve toksisiteyi yükseltmektedir. Bu derlemenin amacı hızla yayılan SC kullanımına ilişkin güncel bilgiler ile SC epidemiyolojisini, kimyasal çeşitliliğini, farmakodinamisini, farmakokinetiğini ve klinik sonuçlarını detaylı bir şekilde sunmak ve Web of Science’ta yayınlanmış sentetik kannabinoidler ile ilgili orijinal makale ve reviewlerin bibliometrik analizini yaparak sentetik kannabinoidler ve çalışma trendine ışık tutmaktır. Method: Elektronik literatürde ‘sentetik kannabinoidler, sentetik kannabinoid epidemiyolojisi, sentetik kannabinoid farmakodinamisi, farmakokinetiği ve klinik etkileri’ anahtar kelimeler ile review için araştırma yapılmıştır. İngilizce ve Türkçe dışında yazılan makaleler çalışmaya dahil edilmemiştir. Bibliometrik analiz için ‘ synthetic cannabin OR K2 OR Spice*’ operatörü ile Web of Science araştırma yapılarak elde edilen veriler WOSviewer uygulaması ile analiz edilmiştir. Bulgular:Yapılan incelemede SC’nin yeni bileşiklerle ortaya çıkmaya ve yaygınlığının artmaya devam ettiği görüldü. SC ilgili yapılan yayınların son yıllarda artış trendinde olduğu ve destekleyen kuruluşların varlığı ile doğru orantılı olarak yayın sayısı ve kalitesinde artış olduğu görüldü. Sonuç: Sentetik kannabinoidler artan kullanım nedeniyle ciddi bir sağlık sorunu haline gelmiştir.

Anahtar Kelimeler

• sentetik kannabinoidler
• CB1 reseptörü
• toksisite
• farmakoloji
• yeni psikoaktif maddeler
• Bibliometrik analiz

Destekleyen Kurum

yok

Etik Beyan

Çalışma elektronik literatür üzerinden yapıldığından etik onay gerekmemektedir.

Synthetic Cannabinoids: A Bibliometric Analysis

Öz

Aim: Synthetic cannabinoids (SC) are one of the fastest-spreading and most concerning classes of new psychoactive substances. Originally synthesized for scientific research, these compounds have rapidly begun to be abused due to their potent psychoactive effects. Compared to Δ9-tetrahydrocannabinol (THC), most SC act as full agonists at cannabinoid receptors, thereby increasing potency and toxicity. The aim of this review is to provide information on the rapidly spreading use of synthetic cannabinoids, including their epidemiology, chemical diversity, pharmacodynamics, pharmacokinetics, and clinical outcomes, and to shed light on the trends in SC research by conducting a bibliometric analysis of original articles and reviews published in the Web of Science. Methods: Electronic literature search was conducted in the electronic literature using the keywords “synthetic cannabinoids, synthetic cannabinoid epidemiology, synthetic cannabinoid pharmacodynamics, pharmacokinetics, and clinical effects” for the review. Articles written in languages other than English and Turkish were excluded from the study. For the bibliometric analysis, data obtained by searching Web of Science using the operator ‘synthetic cannabinoid*’ OR ‘synthetic cannabinoid receptor agonist*’ OR ‘SCRA’ were analyzed using the WOSviewer application. Results: The analysis revealed that synthetic cannabinoids continue to emerge with new compounds and that their prevalence is increasing. The number of publications related to synthetic cannabinoids has shown an upward trend in recent years, supported by the data. Conclusion: Synthetic cannabinoids, which have become a significant health issue due to their increasing use.

Anahtar Kelimeler

• Synthetic cannabinoids
• CB1 receptor
• toxicity
• pharmacology
• novel psychoactive substances
• bibliometric analysis.

Destekleyen Kurum

none

Etik Beyan

Since the study was conducted using electronic literature, ethical approval is not required.

Kaynakça

1. Merlin MD. Man and marijuana: Some Aspects of their Ancient Relationship, Fairleigh Dickinson University Press, 1972, Vancouver, Canada,
2. de Almeida JVM, Conceição NS, Pereira AR, Lyrio MVV et al. Development and Validation of a Cannabinoid Quantification Method in Oil and Marijuana by UHPLC-MS, ACS Omega, 2025 Nov 18;10(47):57385-57393, doi: 10.1021/acsomega.5c07689
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2024: Trends and Developments. Luxembourg: Publications Office of the European Union; 2024.
4. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2025. Vienna: United Nations; 2025.
5. Crocq MA, History of cannabis and the endocannabinoid system, Dialogues Clin Neurosci. 2020 Sep;22(3):223-228. doi: 10.31887/ DCNS.2020.22.3/mcrocq.
6. Di Marzo V, Piscitelli F, The Endocannabinoid System and its Modulation by Phytocannabinoids, Neurotherapeutics. 2015 Oct;12(4):692-8. doi: 10.1007/s13311-015-0374-6.
7. Cristino L, Bisogno T, Di Marzo V, Cannabinoids and the expanded endocannabinoid system in neurological disorders, Nat Rev Neurol. 2020 Jan;16(1):9-29. doi: 10.1038/s41582-019-0284-z,
8. Ricci V, Chiappini S, Martinotti G, Maina G., Acute and long- term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review, Psychiatry Res. 2026:360:117056. doi: 10.1016/j.psychres.2026.117056

9. Gray R, Bressington D, Hughes E, Ivanecka A, A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness, J Psychiatr Ment Health Nurs. 2016;23(5):267-81, doi: 10.1111/jpm.12297
10. Anderson C, Morrell C, Marchevsky D, A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia, BMJ Case Rep. 2015;(6):bcr2015209573, doi: 10.1136/bcr-2015-209573
11. Besli GE, Ikiz MA, Yildirim S, Saltik S, Synthetic Cannabinoid Abuse in Adolescents: A Case Series.Emerg Med. 2015 ;49(5):644- 50, doi: 10.1016/j.jemermed.2015.06.053
12. Schneir AB, Cullen J. Ly BT. “Spice” girls: synthetic cannabinoid intoxication, J Emerg Med. 2011; 40:296-299, doi: 10.1016/j. jemermed.2010.10.014
13. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review, J Emerg Med. 2013; 44:360-366, doi: 10.1016/j. jemermed.2012.07.061
14. Auwӓrter V, Dresen S, Weinmann W. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009; 44:832-837, doi: 10.1002/jms.1558
15. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA, Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications, Drug Alcohol Depend. 2014;144(1):12-41. doi: 10.1016/j.drugalcdep.2014.08.005
16. Liu Q, Liu Y, Ma B, Yi P, Shao R, Li S. et.al. Multilevel metabolic profiling of synthetic cannabinoid 5F-ADB: identifying definitive biomarkers for forensic source tracking and ecotoxicological risk assessment.Environ Toxicol Chem. 2026;45(3):719-730, doi: 10.1093/etojnl/vgag003.
17. Mosca A, Mancusi G, Chiappini S, Miuli A. Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature.Neurosci Biobehav Rev. 2025;179:106431, doi: 10.1016/j.neubiorev.2025.106384.
18. Ng JY, Chang N, A bibliometric analysis of the cannabis and cannabinoid research literature, Journal of Cannabis Research 2022:25(4);6-16, doi: 10.1186/s42238-022-00133-0
19. Agrawal A, Lynskey MT, Madden PA, Pergadia ML, Bucholz KK, Heath AC. Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women. Drug Alcohol Depend. 2009;101(1-2):8–12. doi: 10.1016/j.drugalcdep.2008.10.019
20. Shetty RA, Hill RD, McDonald JA, Sumien N, Forster MJ, Gatch MB. Behavioral pharmacology of novel synthetic indazole, indole, and benzimidazole cannabinoids in rodents, J Cannabis Res. 2026;8(1):22, doi: 10.1186/s42238-026-00390-3
21. Canazza I, Ossato A, Trapella C, Fantinati A, De Luca MA, Margiani G, et al. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology. 2016;233(21–22):3685–70, doi: 10.1007/s00213-016-4402-y
22. Rock KL, Treble R, Copeland CS, Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007- 2022), Front Pharmacol. 2026;29(16):1708335, doi: 10.3389/ fphar.2025.1708335
23. Shen SY, Wu C, Yang ZQ, Wang KX, Shao ZH, Yan W. Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery, Acta Pharmacol Sin. 2025 Jun;46(6):1495-1510. doi: 10.1038/s41401-024-01472-9
24. Al-Qudsi J, Alghamdi M, Bakdash A, Abdelgadir EH, Baggi TR, Kumar S. Analytical method development for detection and quantification of AMB-FUBINACA in mouse brain tissue using GC- MS/MS, J Pharmacol Toxicol Methods. 2026 Mar;138:108420, doi: 10.1016/j.vascn.2026.108420
25. Sharrod-Cole H, Danks J, Holdcroft C, Patel R, Starbrook L. Illicit substances in school-confiscated vapes: Lessons from a laboratory-driven public health pilot, Public Health Pract (Oxf). 2026 Mar 15;11:100770, doi: 10.1016/j.puhip.2026.100770. eCollection 2026 Jun.
26. Laanet PR, Vaher M, Saar-Reismaa P, Micellar electrokinetic chromatography method for the analysis of synthetic and phytocannabinoids, J Chromatogr A. 2022 Jun 21;1673:463080, doi: 10.1016/j.chroma.2022.463080
27. Potts AJ, Cano C, Thomas SHL, Hill S, Synthetic cannabinoid receptor agonists: classification and nomenclature, Clin Toxicol 156 Adli Tıp Dergisi Kamalak et al. (Phila). 2020 Feb;58(2):82-98. doi: 10.1080/15563650.2019.1661425
28. Waugh J, Najafi J, Hawkins L, et al. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. Clin Toxicol. 2016;54(6):512– 518, doi: 10.3109/15563650.2016.1171329
29. Iversen L, Gibbons S. ‘Third generation’ synthetic cannabinoids [Internet]. 2014. [cited 2026 Apr 25]. Available from: https:// www.gov.uk/government/publications/third-generation-synthetic- cannabinoids,
30. Sommer MJ, Grafinger KE, Hermanns-Clausen M, Auwärter V, Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well-documented intoxication cases and basic pharmacological data, Addiction. 2026 Apr;121(4):870-882, doi: 10.1111/add.70268
31. Waters ML, Dargan PI, Yates C, Dines AM, Eyer F, Giraudon I. et al., Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020, Clin. Toxicol. 62 (6) (2024) 378–384, doi: 10.1080/15563650.2024.2346125
32. Cozier GE, Gardner M, Craft S, Skumlien M, Spicer J, Andrews R. et al., Synthetic cannabinoids in e-cigarettes seized from English schools, Addiction 120 (10) (2025) 1995–2004, doi: 10.1111/ add.70110.
33. Pereira RS, Moreira OBO, de Oliveira MAL, Canuto CC, Lemos DOC, Duarte LM et.al. Synthetic cannabinoids in hair: a review of recent findings and analytical methods by LC-MS/MS, Anal Chim Acta. 2026 Mar 15;1391:345078, doi: 10.1016/j.aca.2026.345078
34. Andrews R, Jorge R, Christie R, Gallegos A. From JWH‐018 to OXIZIDS: structural evolution of synthetic cannabinoids in the European Union from 2008 to present day. Drug Test Anal. 2023;15(4):378–387, doi: 10.1002/dta.3422.
35. European Monitoring Centre for Drugs and Drug Addiction . New psychoactive substances: 25 years of early warning and response in Europe Lisbon: EMCDDA; 2022,
36. Cohen K, Weinstein AM. Synthetic and non‐synthetic cannabinoid drugs and their adverse effects‐a review from public health prospective. Front Public Health. 2018;6:162, doi: 10.3389/ fpubh.2018.00162
37. Corazza O, Coloccini S, Marrinan S, Vigar M, Watkins C, Zene C, et al. Novel psychoactive substances in custodial settings: a mixed method investigation on the experiences of people in prison and professionals working with them. Front Psych. 2020;11:460. doi: 10.3389/fpsyt.2020.00460
38. Ralphs R, Williams L, Askew R, Norton A. Adding spice to the porridge: the development of a synthetic cannabinoid market in an English prison. Int J Drug Policy. 2017;40:57–69. doi: 10.1016/j. drugpo.2016.10.003
39. Roque‐Bravo R, Silva RS, Malheiro RF, Carmo H, Carvalho F, da Silva DD, et al. Synthetic cannabinoids: a pharmacological and toxicological overview. Annu Rev Pharmacol Toxicol. 2023;63(1):187– 209, doi: 10.1146/annurev-pharmtox-031122-113758
40. Kong TY, Kim JH, Kim DK, Lee HS. Synthetic cannabinoids are substrates and inhibitors of multiple drug‐metabolizing enzymes. Arch Pharm Res. 2018;41(7):691–710, doi: 10.1007/s12272-018- 1055-x
41. Humayun M, Suarez JI, Shah VA, Neurological Complications of Cannabinoids, Semin Neurol. 2024 Aug;44(4):430-440. doi: 10.1055/ s-0044-1787570,
42. Cooper ZD, Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal, Curr Psychiatry Rep. 2016 May;18(5):52. doi: 10.1007/s11920-016-0694-1
43. Taflaj B, La Maida N, Tittarelli R, Di Trana A, D’Acquarica I, New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects, nt J Mol Sci. 2024 Aug 31;25(17):9484. doi: 10.3390/ijms25179484
44. Christie R, Conlon R, Néfau T, Gallegos A. Semi-synthetic cannabinoids: Recent developments, analytical challenges and strategic responses, Forensic Sci Int. 2026 Apr;381:112823, doi: 10.1016/j.forsciint.2026.112823
45. Shabat S, Hanuš LO, Katzavian G, Gallily R. New canna-bidiol derivatives: synthesis, binding to cannabinoid receptor,and evaluation of their antiinflammatory activity. J Med Chem.2006;49(3):1113–7, doi: 10.1021/jm050709m,
46. Yoganathan P, Claridge H, Chester L, Englund A, Kalk NJ, Copeland CS, Synthetic Cannabinoid-Related Deaths in England, 2012-2019, Cannabis Cannabinoid Res. 2022 Aug;7(4):516-525. doi: 10.1089/can.2020.0161
47. Persson M, Kronstrand R, Evans-Brown M, Green H. In vitro activa-tion of the CB1 receptor by the semi- synthetic cannabinoids hexa-hydrocannabinol (HHC), hexahydrocannabinol acetate (HHC- O)and hexahydrocannabiphorol (HHC-P). Drug Test Anal. 2024;1–7. doi: 10.1002/dta.3750
48. Aldridge JMF, Williams L. Illegal leisure revisited: changing patterns of alcohol and drug use in adolescents and young adults. Drugs Educ Prev Policy. 2012;19:353–35, DOI:10.4324/9780203830468
49. Debruyne D, Monzon E, Perino J, Haramburu F. Daveluy A, Lazes-Charmetant A. et.al. Use of synthetic substances in France and in Europe, Therapie. 2021;76(3):221-228, doi: 10.1016/j. therap.2020.07.005
50. Blavier CAK, Villet MH, Zschiesche A, Auwärter V, Graw M,Geffert C. et.al, Entomological consequences and toxicological detection of synthetic cannabinoid receptor agonists (SCRAs) in necrophagous larvae (Diptera: Calliphoridae) Int J Legal Med. 2026;2: 1349-1365 doi: 10.1007/s00414-025-03688-8
51. Hou X, Wang J, Zhang Y, Zhang Y, Shangguan J, Qin G et. al. Exploring the topic structure and abuse trends of new psychoactive Substance since the 21st century from a bibliometric perspective, Saudi Pharm J. 2024 Apr;32(4):101991. doi: 10.1016/j.jsps.2024.101991
52. Mongan D, Killeen N, Millar SR, Matias J, Keenan E, Galvin B. Hexahydrocannabinol (HHC) use and harms in Ireland: New findings from the 2024 European Web Survey on Drugs, nt J Drug Policy. 2025;145:105011, doi: 10.1016/j.drugpo.2025.10501